In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4 […]
This publication evaluates the real-world use of non-invasive tests (LIVERFASt, FIB-4, and VCTE) in monitoring MASH patients undergoing resmetirom therapy.
This publication explores the relationship between psoriasis severity and liver steatosis using the AI-based LIVERFASt tool. Patients with more severe
Combining LIVERSTAT with Liver Stiffness Measurement (LSM) more effectively identifies advanced liver fibrosis (F3F4) in patients with MASLD, particularly those
Combining LIVERFASt with Liver Stiffness Measurement (LSM) is more effective than FIB-4 & LSM for identifying advanced liver fibrosis in
This publication introduces LIVERFASt, a non-invasive biomarker for predicting liver steatosis and fibrosis in patients with chronic Hepatitis B and
MASLD affects more than 25% of subjects of the general population and can progress to advanced fibrosis (AF) and cirrhosis
Hepatitis C virus (HCV) infection is a common cause of both liver cirrhosis and hepatocellular carcinoma. Successful Direct antiviral agents
AI-based blood tests LIVERSTAT for advanced fibrosis (AF) in patients with T2D can streamline the diagnostic process. Aim of this
The study aims to compare retrospectively two combinations for one-step assessment of advanced fibrosis: LIVERFASt Fibrosis & Liver Stiffness Measurement